Table 3.
Particle shape |
Particle size % Particle <5 µ |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
AR |
CO |
Ci |
AC |
GL |
||||||||
Characteristic | M | SD | M | SD | M | SD | M | SD | M | SD | M | SD |
Exposed* (n = 60) | 0.6 | 0.1 | 0.9 | 0.01 | 0.59 | 0.05 | 0.88 | 0.01 | 69.2 | 16 | 87.4 | 10 |
Nonexposed* (n = 21) | 0.62 | 0.07 | 0.9 | 0.03 | 0.56 | 0.1 | 0.88 | 0.03 | 83 | 21 | 88.9 | 10 |
p = .5 | p = .6 | p = .2 | p = .7 | p = .006 | p = .3 | |||||||
Negative BeLPT† (n = 66) | 0.62 | 0.08 | 0.9 | 0.02 | 0.57 | 0.09 | 0.88 | 0.02 | 73.8 | 19 | 87.7 | 11 |
BeS (n = 9) | 0.57 | 0.1 | 0.9 | 0.01 | 0.61 | 0.05 | 0.88 | 0.01 | 71.2 | 18 | 89.3 | 8.2 |
CBD (n = 6) | 0.6 | 0.03 | 0.89 | 0.01 | 0.58 | 0.04 | 0.88 | 0.01 | 69.3 | 20 | 93.3 | 4 |
p = .3 | p = .6 | p = .9 | p = .7 | p = .5 | p = .2 |
By self-report.
Classification based on BeLPT test and clinical findings.
BeLPT = beryllium lymphocyte proliferation tests; CBD = chronic beryllium disease; BeS = beryllium sensitization. AR = aspect ratio; Co = convexity; Ci = circularity; AC = average concavity; GL = gray level.